Miranda Schmalfuhs
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles
Potential Regulatory & Policy Implications
October 1st 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, explains how can companies position themselves to attract VC/federal funding, and identifies potential regulatory and policy implications of these trends.
Areas That Will Benefit Most From Increased VC/Fed Funding
September 30th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses what specific areas of research and development are likely to benefit the most from this influx of of venture capital and federal funding.
Disposing of Non-Core Assets with Minimal Disruption
September 27th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses strategies companies employ to effectively identify and dispose of non-core assets while minimizing disruption to their operations.
Attracting Top Talent to Mega Campuses
September 26th 2024In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.
Selecting & Developing a Mega Campus
September 25th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, identifies key factors that pharmaceutical and biotech companies should consider when selecting and developing mega campuses.
Telehealth & Its Role in Providing Access to Weight Loss Drugs
September 16th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs
Increasing Access to Legitimate Weight Loss Medications
September 13th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss how UpScriptHealth is working to increase access to legitimate weight loss medications, especially for those in underserved communities.
The Importance of Obtaining Prescriptions from Legitimate Sources
September 11th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, express the importance of obtaining prescriptions from legitimate sources and what can be done to raise awareness among consumers about the dangers.
Commenting on Eli Lilly's Recent Announcement of Offering Zepbound DTC
September 10th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.
Counterfeit Weight Loss Drugs & Potential Health Risks
September 9th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.
